Hereditary breast/ovarian cancer study | Cancer Registry | P-value | ||||
---|---|---|---|---|---|---|
High risk BRCA1+ n (%) | High risk BRCA2+ n (%) | High risk BRCA- n (%) | Low risk n (%) | |||
Breast cancer | ||||||
Laterality | ||||||
Right | 11 (37.9%) | 22 (41.5%) | 153 (48.1%) | 51 (44%) | 2003 (47.4%) | |
Left | 17 (58.6%) | 27 (50.9%) | 155 (48.7%) | 61 (52.6%) | 2142 (50.7%) | |
Bilateral | 1 (3.5%) | 4 (7.6%) | 10 (3.2%) | 4 (3.5%) | 78 (1.8%) | 0.021 (a) |
Total | 29 | 53 | 318 | 116 | 4223 | |
(a) BRCA2+ vs Cancer Registry: OR = 4.3; 95% CI = 1.3 to 11.4 | ||||||
Stage | ||||||
Localized | 10 (40%) | 24 (47.1%) | 154 (57.2%) | 56 (59.6%) | 2396 (57%) | |
Regional | 13 (52%) | 24 (47.1%) | 105 (39%) | 36 (38.3%) | 1618 (38.5%) | |
Advanced | 2 (8%) | 3 (5.9%) | 10 (3.7%) | 2 (2.1%) | 189 (4.5%) | 0.043 (b) |
Total | 25 | 51 | 269 | 94 | 4203 | |
(b) BRCA1/2 vs Cancer Registry | ||||||
Age at diagnosis in years | ||||||
Mean (standard deviation) | 44.3 (8.98) | 44.12 (10.17) | 45.72 (10.34) | 50.14 (11.44) | 60.79 (15.47) | |
Number | 30 | 53 | 327 | 120 | 4384 | |
p-value | < 0.001 | < 0.001 | < 0.001 | < 0.001 | Reference | |
Ovarian cancer | ||||||
Laterality | ||||||
Right | 1 (11.1%) | 0 | 6 (46.2%) | 3 (60%) | 100 (37.2%) | |
Left | 1 (11.1%) | 2 (66.7%) | 3 (23.1%) | 2 (40%) | 86 (32%) | |
Bilateral | 7 (77.8%) | 1 (33.3%) | 4 (30.8%) | 0 | 83 (30.9%) | 0.007 (c) |
Total | 9 | 3 | 13 | 5 | 269 | |
(c) BRCA1+ vs Cancer Registry: OR = 7.8; 95% CI = 1.7 to 55.7 | ||||||
Stage | ||||||
Localized | 1 (9.1%) | 1 (25%) | 6 (25%) | 2 (28.6%) | 28 (23%) | |
Advanced | 10 (90.9%) | 3 (75%) | 18 (75%) | 5 (71.4%) | 94 (77%) | 0.43 (d) |
Total | 11 | 4 | 24 | 7 | 122 | |
(d) BRCA1/2 vs Cancer Registry | ||||||
Age at diagnosis in years | ||||||
Mean (standard deviation) | 54.12 (12.03) | 53.33 (14.68) | 53.29 (10.86) | 54.55 (13.08) | 65.63 (15.43) | |
Number | 13 | 7 | 27 | 8 | 561 | |
p-value | 0.007 | 0.078 | < 0.001 | 0.057 | Reference |